Clinical Trial Search

Primary: Safety as Measured by the Number of Patients With Treatment Emergent Adverse Events (TEAEs), Grade 3 TEAEs, TEAEs Resulting in Death, TEAEs Related to Treatment and…

Primary: Change in NOSE Score — -44.5 units on a scale

Primary: Number of Patients Moving During Pars Plana Vitrectomy (Count of Participants) — 0; 9 participants

Primary: Non-inferiority of RHA® 4 With New Anesthetic Agent Versus RHA® 4-Lidocaine in Terms of Reducing Pain During Device Injection Into Nasolabial Folds. — 17.1; 16.3 mm…

Primary: Change From Baseline to 4 Weeks in WOMAC Pain Score — 2.2332; 2.0287; -0.6387 score on a scale

Primary: Percentage of Participants With a Solicited Injection-site Adverse Event — 4.3; 5.9; 8.7; 8.8 Percentage of participants

Primary: Non-inferiority of RHA® Redensity With New Anesthetic Agent Versus RHA® Redensity With Lidocaine in Terms of Reducing Pain During Device Injection Into the Upper…

Primary: Sum of Pain Intensity Difference (SPID) Over 8 Hours — 35.45; 37.87; 30.70; 36.02 Scores on a scale*hours

Primary: Rate of Viral Rebound at 12 Weeks After Interruption of Antiretroviral Therapy — 13 Participants

Primary: Model-Based Geometric Mean Ratio (GMR) of 24-hour Objective Coughs Per Hour (Week 12/Baseline) — 0.47; 0.48; 0.38 ratio — p=0.041

Primary: Change From Baseline in Daily Average Low Back Pain Intensity (LBPI) Score at Week 6 — 6.48; 6.65; 6.67; -3.58 units on a scale — p=0.001

Primary: Number of Study Participants Experiencing Treatment-Related Toxicity — 0; 0; 1; 9 Participants

Primary: Number of Participants With Morbidity — 0; 0 number of participants

Primary: Number of Participants With Adjudicated Renal Response at Week 52 — 73; 40; 106; 138 Participants — p=<0.001

Primary: Non-inferiority of Fentanyl Nasal Spray Versus Intravenous Opioids in the Change in the Numeric Rating Scale (NRS) Pain Intensity Score at One Hour, Starting From the…